JAIDS Journal of Acquired Immune Deficiency Syndromes:
Basic and Translational Science
T-Cell Subset Distribution in HIV-1–Infected Patients After 12 Years of Treatment-Induced Viremic Suppression
Rönsholt, Frederikke F. MD*; Ullum, Henrik MD, PhD†; Katzenstein, Terese L. MD, PhD, DMSc*; Gerstoft, Jan MD, DMSc*; Ostrowski, Sisse R. MD, PhD, DMSc†
*Department of Infectious Diseases
†Department of Clinical Immunology, Rigshospitalet, Copenhagen, Denmark.
Correspondence to: Frederikke F. Rönsholt, MD, Department of Infectious Diseases, Rigshospitalet, 5132, Blegdamsvej 9, 2100 Copenhagen, Denmark (e-mail: email@example.com).
Supported by the Danish Medical Research Council, The Danish AIDS Foundation, A.P. Møller and wife Chastine Mc-Kinney Møllers Foundation (Fonden til Lægevidenskabens Fremme), and the Augustinus Foundation.
The authors have no conflicts of interest to disclose.
Received February 06, 2012
Accepted May 04, 2012
Objective: Residual immune activation and skewed T cell maturation may contribute to excess comorbidity and mortality in successfully treated HIV-infected patients, and long-term effects of combination antiretroviral therapy (cART) on immune reconstitution remain a debated issue. Quantitative T cell reconstitution and activation and its association with residual viremia in patients with 12 years of viremic suppression were investigated.
Design: Blood samples collected cross-sectionally from 71 HIV-infected patients with cART-induced viremic suppression through 12 years were compared with samples from 16 healthy controls.
Methods: Several different subsets of naive, memory, and activated T cells were analyzed in fresh whole blood by 6-color flowcytometry, and ultrasensitive quantification of HIV RNA was performed.
Results: HIV-infected patients had lower absolute and relative CD4 T cell counts and higher absolute and relative CD8 T cell counts than controls. HIV-infected patients had lower concentrations of naive CD4 cells than controls, but proportions were similar. HIV-infected patients had higher concentrations of CD8+ T cells than controls in all the examined subsets but only a higher proportion of CD8+ cells in the intermediately differentiated and activated subsets. Residual viremia did not correlate to proportions of naive CD4, CD4 recent thymic emigrants, or activated CD8 T cells.
Conclusions: This study demonstrated some degree of T cell imbalance even after 12 years of successful cART. Large longitudinal studies are needed to establish whether these discrete changes have clinical relevance.
The introduction of combination antiretroviral therapy (cART) has improved the prognosis of HIV-infected patients with access to treatment enormously. However, there is evidence of excess comorbidity and mortality among otherwise successfully treated HIV-infected patients due to particularly cardiovascular disease and non–AIDS-defining cancers.1–4 Residual immune activation and dysfunction even after long-term treatment have been suggested as contributory factors of this problem. Several studies have examined the immunological effects of cART, but the long-term effects on immune reconstitution are not clear-cut.
cART effectively induces a decrease in viral load accompanied by an increase in total CD4 count, which is used as a surrogate marker of immune reconstitution. CD4 count in successfully treated patients can continue to increase 8–10 years after treatment initiation.5,6 naive CD4 cells and recent thymic emigrants (RTEs) are depleted in chronic HIV disease and are suggested markers of CD4 recovery because thymic output, which is associated with age and the amount of thymic tissue, correlates with CD4 T cell restoration.7,8
Resting, antigen-experienced T cells are thought to undergo a linear differentiation through several phenotypically distinct subsets: central memory (TCM) and effector memory T cells (TEM), intermediately differentiated T cells (TID), and terminally differentiated T cells (TTD).9 TCM have the capacity to home to secondary lymphoid organs, and TEM display effector functions at the site of inflamed tissue.10 TCM and TEM CD4 cells have been shown to serve as a long-lived reservoir of HIV that prevents eradication of the virus because of the long half-life of these cells.11,12
T cells react to chronic viral infections with distinct phenotypical and functional profiles, that is, HIV-specific T cells primarily display a TID phenotype and play a role in viral control.9,13–16 Progressive disease causes an increase in the magnitude of the HIV-specific CD8 response and a disturbance in the quality of both CD4 and CD8 HIV-specific responses. cART decreases the amount of circulating HIV-specific CD8 cells but whether cART corrects the qualitative displacement remains controversial.13,15,17–19
Immune activation is an important part of the immune response to any acute viral infection, but in HIV infection, immune activation continues and drives disease progression and high levels of cellular immune activation as measured by CD8+CD38+HLA-DR+ T cells that are associated with poorer disease outcome in cART-treated patients.20,21 Although cART effectively reduces, and even in some cases normalizes, these levels,22,23 residual immune activation can persist through years of successful treatment.21,24
The present study investigated T cell subsets in patients with long-term viremic suppression after 12 years of continuous cART to (1) determine the degree of quantitative immune reconstitution and phenotypic T-cell imbalance, particularly excess activation, and (2) examine the relationship between residual viremia and immune activation and reconstitution in patients with long-term viremic suppression.
MATERIALS AND METHODS
The study was conducted at the Department of Infectious Diseases and the Department of Clinical Immunology at Rigshospitalet (Copenhagen, Denmark). The study population comprises a cohort of patients, who were included in between September 1997 and August 1998 on the basis of having reproducible plasma HIV RNA levels <200 copies/mL after starting combination antiretroviral treatment. Several articles based on data from the cohort have previously been published.25–28
One hundred one patients entered the study in 1997 to 1998—at follow up in 2009, 17 of those had died and 13 were lost to follow-up, leaving 71 patients who participated in the present study. Blood samples were obtained in connection with the patients' routine visits to the outpatient clinic, and background data were obtained from the patients' charts and the Danish HIV Cohort.29 All patients gave written informed consent, and the study was approved by the local ethics committee (journal number H-C-2008-077). As treatment interruptions have never been part of the Danish treatment guidelines, the patients received cART continually since the inclusion, although the drug combinations changed over the years because of drug development, side effects, etc. The control group consisted of 16 gender- and age-matched healthy volunteers from the Danish Blood Donor Corps.
T-cell subsets were analyzed in EDTA anticoagulated fresh whole blood by 6-color flowcytometry using a BD FACSCanto II flowcytometer and antibodies stained with fluorescein isothiocyanate (FITC)-CD45, FITC-CD27, FITC CD45RO, FITC-CD31, phycoerythrin (PE)-CD14, PE-CD28, PE-CD38, PE-CD62L, allophycocyanin (APC)-CD45RA, PE-Cy7-CD27, PE-Cy7-HLA-DR, PE-Cy7-CD127, peridinin–chlorophyll–protein complex (PerCP)-CD8, and APC-Cy7-CD4, all from BD Pharmingen (Franklin Lakes, NJ) except PE-Cy7-CD127 from eBioscience (San Diego, CA).
Flowcytometric data were processed with BD FACS Diva software version 5.0.3. The cell definitions used are given in Table 1.9,16,30,31 All analyses were conducted using a lymphocyte gate with <2% CD14+ monocytes, and further distinction of T cells were made by CD4 and CD8 gating. The absolute concentrations of cells were calculated by multiplying the cytometrically derived proportions with the lymphocyte concentrations obtained by standard hematological analysis.
Ultrasensitive HIV RNA Measurements
Quantification of HIV RNA was performed at the AIDS laboratory, Rigshospitalet, on EDTA plasma by an ultrasensitive method based on a modified Amplicor assay (Cobas Amplicor HIV-1 monitor test, version 1.5 ultrasensitive assay; Roche Diagnostics, Branchburg, NJ) to reach a lower level of detection (LLD) of 2.5 copies/mL as used in several other studies.32–35 Plasma was kept at −80°C until analysis. The virus was pelleted from 2 mL of plasma after 2 hours of centrifugation at 23,600 × g at 4°C. Half the normal amount of quantification standard was used, and the RNA pellet was resuspended in 50 μL of diluent. The entire volume of resuspended RNA was assayed by reverse transcriptase polymerase chain reaction according to the manufacturer's instructions. Sixty-four samples were tested with both the above-mentioned method and the local standard TaqMan polymerase chain reaction with LLD = 20 copies/mL and correlated well (Spearman rho = 0.569, P < 0.001).
Statistical analyses were conducted using SPSS 11.5, GraphPad Prism 5.03 and Microsoft Office Excel 2007. For flow cytometric data, means were compared using Mann–Whitney test. Correlation analyses were performed using Spearman rho. All data are presented as medians with interquartile range unless otherwise stated. HIV RNA measurements of <2.5 copies/mL were set as 2.4 copies/mL. P values less than 0.05 were considered significant.
The cohort consisted primarily of white, male HIV-infected patients with a median age of 55 years and a median baseline CD4 count of 0.18 × 109/L. The patients had been diagnosed with HIV for a median of 230 months (range, 143–328 months) and had received cART for a median of 150 months (range, 143–175 months). Nineteen patients had experienced AIDS-defining events, and six patients had chronic hepatitis.
At the date of sampling, 45 patients had HIV RNA <2.5 copies/mL, 17 patients had HIV RNA between 2.5 and 20 copies/mL, 8 patients had HIV RNA between 20 and 128 copies/mL, and 1 patient had 8888 copies/mL. HIV RNA has been measured regularly over the years (between 31 and 68 times) and was below 40 copies/mL, which was the highest applied LLD in the study period, in a median of 86.7% of measurements. Only 7 patients did not experience any blips >40 copies/mL during the entire follow-up.
The control group consisted of 88% male participants with a median age of 56 years. As control subjects were blood donors, they were known to be hepatitis seronegative. The HIV-infected patients had lower concentrations of CD4 T cells and higher concentrations of CD8 T cells than the controls (Figs. 1A, B). When stratified according to baseline CD4 count, the HIV-infected patients showed similar total CD4 gain with ongoing increase even after 12 years of treatment. The flattening slopes of CD4 increase were similar between groups and displayed a good fit to a logarithmic curve (Fig. 1C).
Naive Cells, Naive CD127+ Cells, and RTEs
Two different definitions of naive cells were used to examine both naive cells in the CD27, CD28 maturation pathway, and the expression of CD127 [interleukin (IL)-7 receptor]. HIV-infected patients had lower concentrations of naive CD4 T cells and higher concentrations of naive CD8 T cells than controls (Figs. 2A, D). There were no differences in proportions. Proportions of naive CD4 cells in HIV-infected patients did not correlate with viremia measured by ultrasensitive assay on the same day. Naive CD127+ cells showed a pattern similar to naive cells defined by CD27/CD28 (Figs. 2B, E).
Concentrations of CD4 RTEs did not differ between groups (Fig. 2C), but concentrations of CD8 RTEs were higher in HIV-infected patients than controls (Fig. 2F). Both CD4 and CD8 RTE proportions were similar between groups. Proportions of CD4 RTEs tended toward a negative correlation with age but did not reach significance (Spearman rho = −0.107, P = 0.325) and showed no correlation with viremia on the sample data (data not shown). Patients who had experienced viremic blips above 40 copies/mL during the last 2 years before sampling (n = 39) did not have lower proportions of naive CD4 cells or CD4 RTEs than those with persistent viremic suppression (n = 32) (data not shown).
Central and Effector Memory and Intermediately, Late, and Terminally Differentiated T Cells
In general, only small differences were observed in the CD4 compartment (Figs. 3A–E), and all proportions were similar. Greater differences were seen within the CD8 maturation pathway (Figs. 3F–J), where significant differences were seen for all levels of differentiation, especially within the CD8 TID cells, where not only concentrations but also proportions differed significantly between HIV-infected patients and controls. No differences were found between HIV-infected patients and controls in CD4 TCM and TEM subsets in either concentrations or proportions (Figs. 3A, B). HIV-infected patients had higher concentrations CD8 TCM and TEM than controls (Figs. 3F, G), but there were no differences in proportions.
CD4 TID concentrations were similar between groups whether measured as concentrations or proportions (Fig. 3C), but CD8 TID concentrations (Fig. 3H) were higher compared with controls, and the HIV-infected patients also had higher proportions of CD8 TID cells than controls (P = 0.036), making CD8 TID the only sign of a skewing of the maturation pathway that cannot be explained by higher total CD4 or CD8 counts. CD4 TLD concentrations were lower in HIV-infected patients than controls, but the numbers were exceedingly small and based on few events that might not represent a true difference. CD8 TLD concentrations were higher in HIV-infected patients (Figs. 3D, I). Proportions were similar in both CD4 and CD8 cells. CD4 TTD showed no differences between groups in concentrations (Fig. 3E) or proportions. CD8 TTD concentrations were higher in patients than controls (Fig. 3J), but the proportions were similar.
HIV-infected patients did not show signs of excess activation within the CD4 compartment in either concentrations or proportions (Fig. 4A), but activated CD8 cells were more abundant in HIV-infected patients than controls (Fig. 4B) and constituted a larger percentage of CD8 cells (P = 0.047). CD8 activation did not significantly correlate to viremia measured by ultrasensitive assay on the same day (Fig. 4C), and no correlation was found between viremia and CD8 activation when looking exclusively at the 26 patients with detectable viremia (>2.5 copies/mL) (Spearman rho = 0.306, P = 0.128, data not shown).
The 39 of 71 patients in the study who had experienced one or more viremic blips >40 copies/mL within 2 years before inclusion did not show higher proportions of activated CD8 cells (P = 0.428) than the rest nor did the 7 patients who never experienced any blips during cART treatment differ in activated CD8 proportions from the rest of the study subjects. The patients' percentage of HIV RNA measurements >40 copies/mL during the 12 years of follow-up (frequency of blips) did not correlate to CD8 activation.
The principal findings of the study were as follows: (1) HIV-infected patients differ from controls in having lower absolute and relative CD4 T-cell counts and higher absolute and relative CD8 T-cell counts even after 12 years of successful cART; (2) HIV-infected patients had lower concentrations of naive CD4 cells and naive CD4 cells expressing CD127 than controls but proportions were similar; (3) HIV-infected patients had higher concentrations of CD8+ T cells than controls in all of the examined subsets, but only a higher proportion of CD8+ cells in the TID and activated subset; and (4) residual viremia at the time of sampling or throughout the years did not correlate to the proportions of naive CD4, CD4 RTEs, or activated CD8 T cells.
The study demonstrated that although some successfully treated HIV-infected patients have normalized their levels of total CD4 and CD8 cells, most still have skewed concentrations of both, which impacts on the concentrations of particularly CD8 subsets. This sign of incomplete immune reconstitution has been reported previously in several studies with shorter observation periods.36–38
However, patients with higher baseline CD4 counts reached higher CD4 counts after treatment, and the present study showed evidence of slowing but continuous CD4 gain up to 12 years following a logarithmic curve unaffected by baseline CD4 count. This indicates that even patients with lower baseline might achieve normalization in time, although the parallel slopes imply that the lowest baseline patients will never catch up to the highest baseline patients, unless/until the slopes reach a plateau somewhere beyond 12 years of treatment. Some studies have demonstrated a plateau effect after 3–5 years39,40 but most have shown continuous gain after up to 10 years in line with the present study.5,6,36,41,42
Naive CD4 cells are depleted in untreated HIV infection and to some degree restored by cART. This study showed an incomplete restoration of the naive CD4 cell subset that seems to account for most of the remaining total CD4 deficit. In studies with shorter follow-up periods, both Robbins et al37 and Vrisekoop et al38 found lower concentrations of naive CD4 cells in cART-treated patients with low baseline CD4 count in accordance with our results, and Lederman et al43 demonstrated lower naive concentrations in HIV patients with CD4 counts below 350 per microliter but not in patients with CD4 counts above 500 per microliter.
The IL7/CD127 (IL7 receptor) pathway is critical for the maturation and differentiation of thymocytes, and untreated HIV infection has been shown to be associated with reduced CD127 expression (partly) reversible by cART.44–47 In the present study, concentrations of CD4 naive CD127+ cells were lower in HIV-infected patients than controls, but the proportions did not differ. The results of the naive cells and the naive CD127+ cells were very similar, and the proportions of these subsets correlated well (Spearman rho = 0.991, P < 0.001, data not shown), suggesting that the 2 combinations of surface markers are in fact 2 ways of quantifying the same subset of naive cells.
CD31 has been suggested as a marker of RTEs primarily on CD4 cells,48–50 and as with CD127 expression, untreated HIV infection reduces thymic output, which can be at least partially restored by cART.51,52 Vrisekoop et al38 recently showed normalization of CD31+ naive cells CD4 cells defined as CD45R0−CD27+CD31+ after long-term cART, and the present study did not find signs of downregulation or depletion of cells expressing CD31 in the CD4 compartment.
Thymic function decreases with age, and HIV-infected children undergoing cART show a more efficient immune reconstitution response than adults.51,53,54 However, the thymus has been shown to contribute to the formation of naive cells in HIV-infected adults on cART.7,8 In the present study, the amount of RTEs had returned to normal levels for age, suggesting that the cause of the low naive CD4 levels is not reduced thymic production but may be found elsewhere, that is, in altered peripheral expansion or premature activation.
Based on their functional capabilities and telomere length resting, antigen-experienced cells are thought to undergo a linear differentiation through several phenotypically distinct subsets, and this study examined the whole line of phenotypic differentiation from central memory cells to terminally differentiated cells based on the markers CD45RA, CD27, CD28, and CCR7.9,15 Only few differences in T cell distribution between HIV-infected patients and controls along this maturation line were found, most pronounced in the CD8 compartment where all subsets' concentrations were higher among HIV patients. Only CD8 cells with TID phenotype existed in higher proportions and concentrations.
T cells show different phenotypes according to their viral specificity, and CD8 TID cells are predominant in HIV-specific CD8 cells, whereas other subtypes are more frequent in other latent infections, such as hepatitis C virus or cytomegalovirus.9,10,13,16,55–58 Thus, it is tempting to speculate that the excess of TID CD8 cells could represent accumulation HIV-specific CD8 T cells; however, we found no differences in proportions among the other CD8 subsets indicating a shift toward senescence in the line of differentiation. Other studies have demonstrated disturbances in T cell maturation resulting in skewed representation of particularly CD8 subsets with predominance of preterminally differentiated cells in untreated and to a lesser degree in cART-treated HIV-infected individuals.15,18,59 Skewed maturation of HIV-specific CD4+ T cells toward intermediately and late differentiated subsets has also been described in patients with progressive disease, but cART seems to be able to correct the skewed representation.19
It has been suggested that even cART-treated HIV-infected patients' immune system share some characteristics with that of the elderly (immunosenescence) in terms of reduced T cell renewal, elevated levels of activated T cells, and progressive enrichment of the late and terminally differentiated phenotypes that are CD28− and CD57+ with shortened telomeres and reduced proliferative potential.60–65 These changes are thought to be brought on by viremia, microbial translocation, bystander activation by CMV, and lack of anti-inflammatory mechanisms, such as regulatory T cells. Although the present study confirmed reduced levels of naive CD4 cells, high CD8 TID levels, and excess CD8 activation, thymic output seemed within normal range and the maturation line did not seem severely displaced.
Previous studies that have examined restoration of memory subsets in cART-treated HIV-infected individuals have shorter follow-up, broader definitions of memory cells, or focus solely on CD4 cells. In accordance with our results, Lederman et al43 have described concentrations of TCM and TEM, defined as CD4/CD8+, CD45RA−CCR7+ and CD4/CD8+, CD45RA−CCR7−, respectively, after 2–11 years of cART and found normalization of the CD4 subsets and persistently higher concentrations of the CD8 subsets in patients with total CD4 count above 500 per microliter. Lopez et al59 also found normalization of proportions of 4 CD4 memory subsets defined by CD45RA and CD27 in cART-treated patients compared with controls, but lower proportions of naive CD8 cells and higher proportions of terminally differentiated CD8 cells. Normalization of quantities does not necessarily imply normalization of functional and proliferative capacities and whether cART has potential to correct these qualitative disturbances remains controversial13,17–19,66 and is beyond the scope of this study.
The present study showed persistent CD8 activation after 12 years of continuous cART demonstrated by greater proportions and concentrations of activated T cells but no signs of excess activation within the CD4 subset. Even though CD8 activation persists after long-term cART, it is noteworthy that in some patients proportions do normalize and it is unclear what factors determine this. Several studies have examined activated T cells after cART and the results are contradictory. In all studies, cART reduces immune activation but some studies show persistent residual activation in CD4 and/or CD8 compartments,21,24,37 whereas others demonstrate normalization in one or both compartments.38,43
In this study, no correlation between CD8 activation and low-grade viremia was found, but all patients except one had HIV RNA below 128 copies/mL, and the 2 factors are probably dependent when viral load is substantially higher, that is, over 10,000 copies/mL as shown elsewhere.22,23,59,67 Patients who experienced viremic blips >40 copies/mL within the last 2 years were not prone to higher levels of activated CD8 cells. This is somewhat in contrast to findings in previous articles based on data from the same cohort that found that patients who experienced blips within the first 6 to 24 months of treatment had significantly higher levels of activated CD8 cells.26 This difference suggests that the immune system is less sensitive to viremic blips after several years of immune reconstitution, but undiagnosed viremia between samples and the difference in the assays over the course of time may also be an influencing factor.
The strengths of the study are the long observation period without scheduled treatment interruptions and the possibility to examine several T-cell subsets. The limitations are primarily the cross-sectional design and the lack of qualitative assays that could contribute to describe a potential difference in the cells' functional and proliferative capabilities. Controls were relatively few and only matched on gender and age. Another consideration is that T cell composition and reconstitution in lymphoid tissue (ie, in the gut, where most CD4 T cells reside) may not be reflected in circulating cells.68 It remains to be determined which factors are responsible for the immune imbalance that exists after years of effective viral suppression, and large longitudinal studies are needed to establish whether these discrete changes have any clinical relevance.
In conclusion, the results demonstrate that some degree of T-cell imbalance persists after 12 years of successful cART, namely, in the shape of (1) reduced CD4 counts and elevated CD8 counts, (2) reduced concentrations of naive CD4 cells, and (3) elevated levels of intermediately differentiated and activated CD8 cells. Additionally, the study found no association between low-grade viremia and immune reconstitution and activation.
Author Contributions: Study concept and design: S. R. Ostrowski, T. L. Katzenstein, H. Ullum, J. Gerstoft, F. F. Rönsholt. Conduct of the study: F. F. Rönsholt. Data analysis: F. F. Rönsholt, S. R. Ostrowski, T. L. Katzenstein, J. Gerstoft, H. Ullum. Drafting the manuscript: F. F. Rönsholt. All authors critically reviewed content and approved final version for publication.
1. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009;338:a3172.
2. Hasse B, Ledergerber B, Furrer H, et al.. Morbidity and aging in HIV-infected persons: the Swiss HIV Cohort Study. Clin Infect Dis. 2011;53:1130–1139.
3. Silverberg MJ, Chao C, Leyden WA, et al.. HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009;23:2337–2345.
4. Triant VA, Lee H, Hadigan C, et al.. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506–2512.
5. Guihot A, Tubiana R, Breton G, et al.. Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. AIDS. 2010;24:614–617.
6. Hughes R, Sterne J, Walsh J, et al.. Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study. HIV Med. 2011;12:583–593.
7. Li T, Wu N, Dai Y, et al.. Reduced thymic output is a major mechanism of immune reconstitution failure in HIV-infected patients after long-term antiretroviral therapy. Clin Infect Dis. 2011;53:944–951.
8. Kolte L, Dreves AM, Ersboll AK, et al.. Association between larger thymic size and higher thymic output in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. J Infect Dis. 2002;185:1578–1585.
9. Appay V, van Lier RA, Sallusto F, et al.. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A. 2008;73:975–983.
10. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22:745–763.
11. Chomont N, El-Far M, Ancuta P, et al.. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15:893–900.
12. Chomont N, DaFonseca S, Vandergeeten C, et al.. Maintenance of CD4+ T-cell memory and HIV persistence: keeping memory, keeping HIV. Curr Opin HIV AIDS. 2011;6:30–36.
13. Appay V, Nixon DF, Donahoe SM, et al.. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med. 2000;192:63–75.
14. McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. Nature. 2001;410:980–987.
15. Champagne P, Ogg GS, King AS, et al.. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature. 2001;410:106–111.
16. Yue FY, Kovacs CM, Dimayuga RC, et al.. HIV-1-specific memory CD4+ T cells are phenotypically less mature than cytomegalovirus-specific memory CD4+ T cells. J Immunol. 2004;172:2476–2486.
17. Pohling J, Zipperlen K, Hollett NA, et al.. Human immunodeficiency virus type I-specific CD8+ T cell subset abnormalities in chronic infection persist through effective antiretroviral therapy. BMC Infect Dis. 2010;10:129.
18. Rehr M, Cahenzli J, Haas A, et al.. Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy. J Virol. 2008;82:3391–3404.
19. Harari A, Petitpierre S, Vallelian F, et al.. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood. 2004;103:966–972.
20. Mildvan D, Bosch RJ, Kim RS, et al.. Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. J Infect Dis. 2004;189:1811–1820.
21. Hunt PW. T cell activation is associated with lower CD4+ cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534–1543.
22. Deeks SG, Kitchen CM, Liu L, et al.. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood. 2004;104:942–947.
23. Tilling R, Kinloch S, Goh LE, et al.. Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. AIDS. 2002;16:589–596.
24. Anthony KB, Yoder C, Metcalf JA, et al.. Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J Acquir Immune Defic Syndr. 2003;33:125–133.
25. Katzenstein TL, Ullum H, Roge BT, et al.. Virological and immunological profiles among patients with undetectable viral load followed prospectively for 24 months. HIV Med. 2003;4:53–61.
26. Ostrowski SR, Katzenstein TL, Thim PT, et al.. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy. J Infect Dis. 2005;191:348–357.
27. Ostrowski SR, Ullum H, Pedersen BK, et al.. 2B4 expression on natural killer cells increases in HIV-1 infected patients followed prospectively during highly active antiretroviral therapy. Clin Exp Immunol. 2005;141:526–533.
28. Ostrowski SR, Katzenstein TL, Pedersen BK, et al.. Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers. Scand J Immunol. 2008;68:652–660.
29. Obel N, Engsig FN, Rasmussen LD, et al.. Cohort profile: the Danish HIV Cohort Study. Int J Epidemiol. 2009;38:1202–1206.
30. Chattopadhyay PK, Roederer M. Good cell, bad cell: flow cytometry reveals T-cell subsets important in HIV disease. Cytometry A. 2010;77:614–622.
31. Ostrowski SR. Immune activation in chronic HIV infection. Dan Med Bull. 2010;57:B4122.
32. Bonora S, Nicastri E, Calcagno A, et al.. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. J Med Virol. 2009;81:400–405.
33. Palmisano L, Giuliano M, Nicastri E, et al.. Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapy. AIDS. 2005;19:1843–1847.
34. Havlir DV, Strain MC, Clerici M, et al.. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol. 2003;77:11212–11219.
35. Havlir DV, Bassett R, Levitan D, et al.. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA. 2001;286:171–179.
36. Kelley CF, Kitchen CM, Hunt PW, et al.. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis. 2009;48:787–794.
37. Robbins GK, Spritzler JG, Chan ES, et al.. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis. 2009;48:350–361.
38. Vrisekoop N, van GR, de Boer AB, et al.. Restoration of the CD4 T cell compartment after long-term highly active antiretroviral therapy without phenotypical signs of accelerated immunological aging. J Immunol. 2008;181:1573–1581.
39. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007;44:441–446.
40. Kaufmann GR, Perrin L, Pantaleo G, et al.. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med. 2003;163:2187–2195.
41. Mocroft A, Phillips AN, Gatell J, et al.. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet. 2007;370:407–413.
42. Landay A, da Silva BA, King MS, et al.. Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis. 2007;44:749–754.
43. Lederman MM, Calabrese L, Funderburg NT, et al.. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis. 2011;204:1217–1226.
44. Rose T, Lambotte O, Pallier C, et al.. Identification and biochemical characterization of human plasma soluble IL-7R: lower concentrations in HIV-1-infected patients. J Immunol. 2009;182:7389–7397.
45. Colle JH, Moreau JL, Fontanet A, et al.. Regulatory dysfunction of the interleukin-7 receptor in CD4 and CD8 lymphocytes from HIV-infected patients—effects of antiretroviral therapy. J Acquir Immune Defic Syndr. 2006;42:277–285.
46. Colle JH, Moreau JL, Fontanet A, et al.. CD127 expression and regulation are altered in the memory CD8 T cells of HIV-infected patients—reversal by highly active anti-retroviral therapy (HAART). Clin Exp Immunol. 2006;143:398–403.
47. Camargo JF, Kulkarni H, Agan BK, et al.. Responsiveness of T cells to interleukin-7 is associated with higher CD4+ T cell counts in HIV-1-positive individuals with highly active antiretroviral therapy-induced viral load suppression. J Infect Dis. 2009;199:1872–1882.
48. Kimmig S, Przybylski GK, Schmidt CA, et al.. Two subsets of naive T helper cells with distinct T cell receptor excision circle content in human adult peripheral blood. J Exp Med. 2002;195:789–794.
49. Kohler S, Thiel A. Life after the thymus: CD31+ and CD31-human naive CD+ T-cell subsets. Blood. 2009;113:769–774.
50. Tanaskovic S, Fernandez S, Price P, et al.. CD31 (PECAM-1) is a marker of recent thymic emigrants among CD4+ T-cells, but not CD8+ T-cells or gammadelta T-cells, in HIV patients responding to ART. Immunol Cell Biol. 2010;88:321–327.
51. Douek DC, McFarland RD, Keiser PH, et al.. Changes in thymic function with age and during the treatment of HIV infection. Nature. 1998;396:690–695.
52. Douek DC, Betts MR, Hill BJ, et al.. Evidence for increased T cell turnover and decreased thymic output in HIV infection. J Immunol. 2001;167:6663–6668.
53. Resino S, Seoane E, Perez A, et al.. Different profiles of immune reconstitution in children and adults with HIV-infection after highly active antiretroviral therapy. BMC Infect Dis. 2006;6:112.
54. Franco JM, Leon-Leal JA, Leal M, et al.. CD4+ and CD8+ T lymphocyte regeneration after anti-retroviral therapy in HIV-1-infected children and adult patients. Clin Exp Immunol. 2000;119:493–498.
55. Appay V, Dunbar PR, Callan M, et al.. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002;8:379–385.
56. Papagno L, Spina CA, Marchant A, et al.. Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol. 2004;2:E20.
57. Almeida JR, Price DA, Papagno L, et al.. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med. 2007;204:2473–2485.
58. Nomura LE, Emu B, Hoh R, et al.. IL-2 production correlates with effector cell differentiation in HIV-specific CD8+ T cells. AIDS Res Ther. 2006;3:18.
59. Lopez M, Soriano V, Peris-Pertusa A, et al.. Elite controllers display higher activation on central memory CD8 T cells than HIV patients successfully on HAART. AIDS Res Hum Retroviruses. 2011;27:157–165.
60. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141–155.
61. Desai S, Landay A. Early immune senescence in HIV disease. Curr HIV/AIDS Rep. 2010;7:4–10.
62. Kalayjian RC, Landay A, Pollard RB, et al.. Age-related immune dysfunction in health and in human immunodeficiency virus (HIV) disease: association of age and HIV infection with naive CD8+ cell depletion, reduced expression of CD28 on CD8+ cells, and reduced thymic volumes. J Infect Dis. 2003;187:1924–1933.
63. Sansoni P, Vescovini R, Fagnoni F, et al.. The immune system in extreme longevity. Exp Gerontol. 2008;43:61–65.
64. Onyema OO, Njemini R, Bautmans I, et al.. Cellular aging and senescence characteristics of human T-lymphocytes. Biogerontology. 2012;13:169–181.
65. Olsson J, Wikby A, Johansson B, et al.. Age-related change in peripheral blood T-lymphocyte subpopulations and cytomegalovirus infection in the very old: the Swedish longitudinal OCTO immune study. Mech Ageing Dev. 2000;121:187–201.
66. Elrefaei M, McElroy MD, Preas CP, et al.. Central memory CD4+ T cell responses in chronic HIV infection are not restored by antiretroviral therapy. J Immunol. 2004;173:2184–2189.
67. Steel A, John L, Shamji MH, et al.. CD38 expression on CD8 T cells has a weak association with CD4 T-cell recovery and is a poor marker of viral replication in HIV-1-infected patients on antiretroviral therapy. HIV Med. 2008;9:118–125.
68. Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe? Nat Immunol. 2006;7:235–239.
This article has been cited 1 time(s).
Future VirologyHIV-1 and the immune response to TBFuture Virology
HIV-1; T-lymphocyte subsets; immune reconstitution; antiretroviral therapy; FACS; viral load
© 2012 Lippincott Williams & Wilkins, Inc.
Highlight selected keywords in the article text.